Brain cancer therapies show promise at SNO meeting
This article was originally published in Scrip
Executive Summary
At least four brain cancer therapies and a device showed improvements versus both historical trends in glioblastoma (GBM) and controls during the recent Society for Neuro-Oncology (SNO) annual scientific meeting, including a gene-activated prodrug, an immunotherapy, a hypoxia-targeting agent, an antibody-drug conjugate and a device.